Prevention & lipidsCohort study
Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting
- Retrospective cohort study
- multicentre
Authors' conclusion
Our findings supported the safety of currently recommended target of LDL-C control and the 'lower is better' principle in patients with ASCVD.
Study context
- Population
- Patients with documented atherosclerotic cardiovascular disease (ASCVD) on statin treatment for ≥3 months, electronic health records, China
- Participants
- 33,968 patients
- Exposure
- Post-treatment LDL-C <1.4 mmol/L vs ≥3.4 mmol/L
- Outcome
- All-cause mortality, CV mortality and non-CV mortality
- Follow-up
- Median 47 months
Main finding
As reported in the abstract
LDL-C <1.4 mmol/L vs LDL-C ≥ 3.4 mmol/LEstimate (95% CI)
all-cause mortality
HR 0.77(0.69–0.86)
CV mortality
subdistribution HR 0.68(0.58–0.79)
Observational data: associations, not effects.
Further findings
Subgroups (intensity of LDL-C reduction and others)
- Survival benefit consistent across subgroups
Original publication
Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting. Eur J Prev Cardiol. Published 15 November 2023. doi:10.1093/eurjpc/zwad354
Summarised from the published abstract; every number is checked against it